nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—Ethinyl Estradiol—prostate cancer	0.219	0.37	CbGbCtD
Rifaximin—CYP3A4—prostate cancer	0.2	1	CbGaD
Rifaximin—NR1I2—Estradiol—prostate cancer	0.141	0.238	CbGbCtD
Rifaximin—NR1I2—Docetaxel—prostate cancer	0.0843	0.142	CbGbCtD
Rifaximin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0306	0.0517	CbGbCtD
Rifaximin—CYP3A4—Bicalutamide—prostate cancer	0.0161	0.0271	CbGbCtD
Rifaximin—CYP3A4—Estramustine—prostate cancer	0.0149	0.0252	CbGbCtD
Rifaximin—CYP3A4—Abiraterone—prostate cancer	0.0133	0.0225	CbGbCtD
Rifaximin—CYP3A4—Flutamide—prostate cancer	0.0133	0.0225	CbGbCtD
Rifaximin—CYP3A4—Cabazitaxel—prostate cancer	0.00986	0.0166	CbGbCtD
Rifaximin—CYP3A4—Estrone—prostate cancer	0.00963	0.0163	CbGbCtD
Rifaximin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00859	0.0145	CbGbCtD
Rifaximin—CYP3A4—Conjugated Estrogens—prostate cancer	0.0063	0.0106	CbGbCtD
Rifaximin—CYP3A4—Mitoxantrone—prostate cancer	0.00573	0.00967	CbGbCtD
Rifaximin—CYP3A4—Estradiol—prostate cancer	0.00553	0.00934	CbGbCtD
Rifaximin—CYP3A4—Prednisone—prostate cancer	0.00476	0.00803	CbGbCtD
Rifaximin—CYP3A4—Etoposide—prostate cancer	0.00361	0.0061	CbGbCtD
Rifaximin—CYP3A4—Docetaxel—prostate cancer	0.00331	0.00558	CbGbCtD
Rifaximin—Rifabutin—HSP90B1—prostate cancer	0.00296	0.481	CrCbGaD
Rifaximin—CYP3A4—Doxorubicin—prostate cancer	0.00246	0.00416	CbGbCtD
Rifaximin—Rifapentine—CYP3A43—prostate cancer	0.00118	0.191	CrCbGaD
Rifaximin—Rifampicin—CYP3A43—prostate cancer	0.000736	0.119	CrCbGaD
Rifaximin—Rifapentine—CYP3A5—prostate cancer	0.000296	0.0479	CrCbGaD
Rifaximin—Rifampicin—CYP3A5—prostate cancer	0.000184	0.0299	CrCbGaD
Rifaximin—Rifampicin—CYP2A6—prostate cancer	0.000179	0.029	CrCbGaD
Rifaximin—Rifabutin—CYP3A4—prostate cancer	0.000169	0.0274	CrCbGaD
Rifaximin—Rifapentine—CYP3A4—prostate cancer	0.000128	0.0208	CrCbGaD
Rifaximin—Rifampicin—CYP2E1—prostate cancer	0.000127	0.0206	CrCbGaD
Rifaximin—Rifampicin—CYP2C19—prostate cancer	0.000126	0.0204	CrCbGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PARP1—prostate cancer	0.000106	0.00258	CbGpPWpGaD
Rifaximin—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	0.000104	0.00253	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR2—prostate cancer	0.0001	0.00244	CbGpPWpGaD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	9.98e-05	0.00243	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	9.9e-05	0.00241	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MBD2—prostate cancer	9.53e-05	0.00232	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—TET2—prostate cancer	9.53e-05	0.00232	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	9.45e-05	0.0023	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RPL12—prostate cancer	9.35e-05	0.00228	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NCOA1—prostate cancer	9.22e-05	0.00225	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	9.08e-05	0.00221	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	8.97e-05	0.00218	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—AR—prostate cancer	8.84e-05	0.00215	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	8.82e-05	0.00215	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—RXRA—prostate cancer	8.77e-05	0.00214	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	8.71e-05	0.00212	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—EIF3A—prostate cancer	8.58e-05	0.00209	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	8.53e-05	0.00208	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	8.11e-05	0.00198	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	8.11e-05	0.00198	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	8.02e-05	0.00195	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	8e-05	0.00195	CbGpPWpGaD
Rifaximin—Rifampicin—CYP3A4—prostate cancer	7.99e-05	0.013	CrCbGaD
Rifaximin—NR1I2—Generic Transcription Pathway—VDR—prostate cancer	7.95e-05	0.00194	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	7.63e-05	0.00186	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTM3—prostate cancer	7.63e-05	0.00186	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	7.52e-05	0.00183	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	7.52e-05	0.00183	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	7.42e-05	0.00181	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	7.36e-05	0.00179	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	7.31e-05	0.00178	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	7.23e-05	0.00176	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—NAT1—prostate cancer	7.23e-05	0.00176	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—DNMT3B—prostate cancer	7.22e-05	0.00176	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	7.21e-05	0.00176	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	7.15e-05	0.00174	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NR3C1—prostate cancer	7.15e-05	0.00174	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	7.13e-05	0.00174	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RPL10—prostate cancer	7.08e-05	0.00173	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	7.05e-05	0.00172	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	7.03e-05	0.00171	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	6.96e-05	0.0017	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HIST1H2BG—prostate cancer	6.95e-05	0.00169	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	6.75e-05	0.00165	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NPPA—prostate cancer	6.72e-05	0.00164	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HIST1H4H—prostate cancer	6.72e-05	0.00164	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARA—prostate cancer	6.7e-05	0.00163	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	6.67e-05	0.00162	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	6.61e-05	0.00161	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MED12—prostate cancer	6.61e-05	0.00161	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	6.44e-05	0.00157	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	6.21e-05	0.00151	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR1—prostate cancer	6.07e-05	0.00148	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	6.06e-05	0.00148	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	6e-05	0.00146	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	5.93e-05	0.00144	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	5.92e-05	0.00144	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	5.72e-05	0.00139	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	5.69e-05	0.00138	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	5.62e-05	0.00137	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RPS19—prostate cancer	5.62e-05	0.00137	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	5.61e-05	0.00137	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	5.55e-05	0.00135	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	5.48e-05	0.00134	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	5.48e-05	0.00133	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	5.42e-05	0.00132	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	5.41e-05	0.00132	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—DNMT1—prostate cancer	5.37e-05	0.00131	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	5.35e-05	0.0013	CbGpPWpGaD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	5.33e-05	0.0013	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—CREBBP—prostate cancer	5.32e-05	0.0013	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	5.27e-05	0.00128	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NCOA2—prostate cancer	5.27e-05	0.00128	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	5.22e-05	0.00127	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—EZH2—prostate cancer	5.2e-05	0.00127	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	5.16e-05	0.00126	CbGpPWpGaD
Rifaximin—Dry mouth—Capecitabine—prostate cancer	5.11e-05	0.000319	CcSEcCtD
Rifaximin—Vomiting—Estradiol—prostate cancer	5.11e-05	0.000319	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—prostate cancer	5.09e-05	0.000318	CcSEcCtD
Rifaximin—Gastrointestinal pain—Etoposide—prostate cancer	5.09e-05	0.000318	CcSEcCtD
Rifaximin—Shock—Docetaxel—prostate cancer	5.09e-05	0.000318	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—PARP1—prostate cancer	5.09e-05	0.00124	CbGpPWpGaD
Rifaximin—Nervous system disorder—Docetaxel—prostate cancer	5.07e-05	0.000317	CcSEcCtD
Rifaximin—Ill-defined disorder—Prednisone—prostate cancer	5.07e-05	0.000317	CcSEcCtD
Rifaximin—Rash—Estradiol—prostate cancer	5.06e-05	0.000316	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—prostate cancer	5.06e-05	0.000316	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—prostate cancer	5.06e-05	0.000316	CcSEcCtD
Rifaximin—Dermatitis—Estradiol—prostate cancer	5.06e-05	0.000316	CcSEcCtD
Rifaximin—Anaemia—Prednisone—prostate cancer	5.05e-05	0.000316	CcSEcCtD
Rifaximin—Confusional state—Capecitabine—prostate cancer	5.05e-05	0.000315	CcSEcCtD
Rifaximin—Headache—Estradiol—prostate cancer	5.03e-05	0.000314	CcSEcCtD
Rifaximin—Skin disorder—Docetaxel—prostate cancer	5.03e-05	0.000314	CcSEcCtD
Rifaximin—Angioedema—Prednisone—prostate cancer	5e-05	0.000312	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—SERPINE1—prostate cancer	4.99e-05	0.00122	CbGpPWpGaD
Rifaximin—Infection—Capecitabine—prostate cancer	4.98e-05	0.000311	CcSEcCtD
Rifaximin—Urticaria—Etoposide—prostate cancer	4.95e-05	0.000309	CcSEcCtD
Rifaximin—Haemoglobin—Epirubicin—prostate cancer	4.94e-05	0.000308	CcSEcCtD
Rifaximin—Anorexia—Docetaxel—prostate cancer	4.93e-05	0.000308	CcSEcCtD
Rifaximin—Malaise—Prednisone—prostate cancer	4.93e-05	0.000308	CcSEcCtD
Rifaximin—Shock—Capecitabine—prostate cancer	4.93e-05	0.000308	CcSEcCtD
Rifaximin—Rhinitis—Epirubicin—prostate cancer	4.92e-05	0.000308	CcSEcCtD
Rifaximin—Body temperature increased—Etoposide—prostate cancer	4.92e-05	0.000307	CcSEcCtD
Rifaximin—Abdominal pain—Etoposide—prostate cancer	4.92e-05	0.000307	CcSEcCtD
Rifaximin—Nervous system disorder—Capecitabine—prostate cancer	4.91e-05	0.000307	CcSEcCtD
Rifaximin—Vertigo—Prednisone—prostate cancer	4.91e-05	0.000307	CcSEcCtD
Rifaximin—Haemorrhage—Epirubicin—prostate cancer	4.91e-05	0.000307	CcSEcCtD
Rifaximin—Syncope—Prednisone—prostate cancer	4.9e-05	0.000306	CcSEcCtD
Rifaximin—Hypoaesthesia—Epirubicin—prostate cancer	4.89e-05	0.000305	CcSEcCtD
Rifaximin—Pharyngitis—Epirubicin—prostate cancer	4.88e-05	0.000304	CcSEcCtD
Rifaximin—Skin disorder—Capecitabine—prostate cancer	4.87e-05	0.000304	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	4.86e-05	0.00118	CbGpPWpGaD
Rifaximin—Urinary tract disorder—Epirubicin—prostate cancer	4.85e-05	0.000303	CcSEcCtD
Rifaximin—Hyperhidrosis—Capecitabine—prostate cancer	4.84e-05	0.000302	CcSEcCtD
Rifaximin—Oedema peripheral—Epirubicin—prostate cancer	4.84e-05	0.000302	CcSEcCtD
Rifaximin—Hypotension—Docetaxel—prostate cancer	4.83e-05	0.000302	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—prostate cancer	4.83e-05	0.000301	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	4.83e-05	0.00118	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ESR2—prostate cancer	4.82e-05	0.00117	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HSPA1A—prostate cancer	4.82e-05	0.00117	CbGpPWpGaD
Rifaximin—Urethral disorder—Epirubicin—prostate cancer	4.82e-05	0.000301	CcSEcCtD
Rifaximin—Loss of consciousness—Prednisone—prostate cancer	4.81e-05	0.0003	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—prostate cancer	4.78e-05	0.000298	CcSEcCtD
Rifaximin—Anorexia—Capecitabine—prostate cancer	4.78e-05	0.000298	CcSEcCtD
Rifaximin—Nausea—Estradiol—prostate cancer	4.77e-05	0.000298	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	4.76e-05	0.00116	CbGpPWpGaD
Rifaximin—Vomiting—Mitoxantrone—prostate cancer	4.76e-05	0.000297	CcSEcCtD
Rifaximin—Rash—Mitoxantrone—prostate cancer	4.72e-05	0.000295	CcSEcCtD
Rifaximin—Dermatitis—Mitoxantrone—prostate cancer	4.71e-05	0.000294	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.71e-05	0.000294	CcSEcCtD
Rifaximin—Headache—Mitoxantrone—prostate cancer	4.69e-05	0.000293	CcSEcCtD
Rifaximin—Hypotension—Capecitabine—prostate cancer	4.68e-05	0.000292	CcSEcCtD
Rifaximin—Insomnia—Docetaxel—prostate cancer	4.68e-05	0.000292	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA3—prostate cancer	4.66e-05	0.00114	CbGpPWpGaD
Rifaximin—Arthralgia—Prednisone—prostate cancer	4.65e-05	0.000291	CcSEcCtD
Rifaximin—Myalgia—Prednisone—prostate cancer	4.65e-05	0.000291	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.62e-05	0.000289	CcSEcCtD
Rifaximin—Dyspnoea—Docetaxel—prostate cancer	4.61e-05	0.000288	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	4.61e-05	0.00112	CbGpPWpGaD
Rifaximin—Discomfort—Prednisone—prostate cancer	4.6e-05	0.000287	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	4.6e-05	0.00112	CbGpPWpGaD
Rifaximin—Hypersensitivity—Etoposide—prostate cancer	4.59e-05	0.000286	CcSEcCtD
Rifaximin—Tinnitus—Epirubicin—prostate cancer	4.58e-05	0.000286	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—prostate cancer	4.57e-05	0.000285	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.56e-05	0.000285	CcSEcCtD
Rifaximin—Flushing—Epirubicin—prostate cancer	4.56e-05	0.000285	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—prostate cancer	4.56e-05	0.000285	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—prostate cancer	4.55e-05	0.000284	CcSEcCtD
Rifaximin—Insomnia—Capecitabine—prostate cancer	4.53e-05	0.000283	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—prostate cancer	4.52e-05	0.000282	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—prostate cancer	4.51e-05	0.000282	CcSEcCtD
Rifaximin—Decreased appetite—Docetaxel—prostate cancer	4.5e-05	0.000281	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—prostate cancer	4.49e-05	0.00028	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—prostate cancer	4.48e-05	0.00028	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Docetaxel—prostate cancer	4.47e-05	0.000279	CcSEcCtD
Rifaximin—Asthenia—Etoposide—prostate cancer	4.47e-05	0.000279	CcSEcCtD
Rifaximin—Dyspnoea—Capecitabine—prostate cancer	4.47e-05	0.000279	CcSEcCtD
Rifaximin—Anaphylactic shock—Prednisone—prostate cancer	4.46e-05	0.000279	CcSEcCtD
Rifaximin—Fatigue—Docetaxel—prostate cancer	4.46e-05	0.000279	CcSEcCtD
Rifaximin—Angiopathy—Epirubicin—prostate cancer	4.46e-05	0.000278	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—prostate cancer	4.46e-05	0.000278	CcSEcCtD
Rifaximin—Nausea—Mitoxantrone—prostate cancer	4.45e-05	0.000278	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NCOA1—prostate cancer	4.44e-05	0.00108	CbGpPWpGaD
Rifaximin—Infection—Prednisone—prostate cancer	4.43e-05	0.000277	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—prostate cancer	4.43e-05	0.000276	CcSEcCtD
Rifaximin—Pain—Docetaxel—prostate cancer	4.42e-05	0.000276	CcSEcCtD
Rifaximin—Constipation—Docetaxel—prostate cancer	4.42e-05	0.000276	CcSEcCtD
Rifaximin—Pruritus—Etoposide—prostate cancer	4.4e-05	0.000275	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	4.4e-05	0.00107	CbGpPWpGaD
Rifaximin—Shock—Prednisone—prostate cancer	4.39e-05	0.000274	CcSEcCtD
Rifaximin—Nervous system disorder—Prednisone—prostate cancer	4.38e-05	0.000273	CcSEcCtD
Rifaximin—Decreased appetite—Capecitabine—prostate cancer	4.35e-05	0.000272	CcSEcCtD
Rifaximin—Skin disorder—Prednisone—prostate cancer	4.33e-05	0.000271	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	4.33e-05	0.00106	CbGpPWpGaD
Rifaximin—Gastrointestinal disorder—Capecitabine—prostate cancer	4.32e-05	0.00027	CcSEcCtD
Rifaximin—Fatigue—Capecitabine—prostate cancer	4.32e-05	0.00027	CcSEcCtD
Rifaximin—Hyperhidrosis—Prednisone—prostate cancer	4.31e-05	0.000269	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	4.31e-05	0.00105	CbGpPWpGaD
Rifaximin—Mental disorder—Epirubicin—prostate cancer	4.3e-05	0.000269	CcSEcCtD
Rifaximin—Constipation—Capecitabine—prostate cancer	4.28e-05	0.000267	CcSEcCtD
Rifaximin—Pain—Capecitabine—prostate cancer	4.28e-05	0.000267	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—prostate cancer	4.28e-05	0.000267	CcSEcCtD
Rifaximin—Feeling abnormal—Docetaxel—prostate cancer	4.26e-05	0.000266	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA4—prostate cancer	4.26e-05	0.00104	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	4.26e-05	0.00104	CbGpPWpGaD
Rifaximin—Diarrhoea—Etoposide—prostate cancer	4.26e-05	0.000266	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—AR—prostate cancer	4.26e-05	0.00104	CbGpPWpGaD
Rifaximin—Anorexia—Prednisone—prostate cancer	4.25e-05	0.000266	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	4.25e-05	0.00104	CbGpPWpGaD
Rifaximin—Tinnitus—Doxorubicin—prostate cancer	4.24e-05	0.000265	CcSEcCtD
Rifaximin—Gastrointestinal pain—Docetaxel—prostate cancer	4.23e-05	0.000264	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—RXRA—prostate cancer	4.22e-05	0.00103	CbGpPWpGaD
Rifaximin—Flushing—Doxorubicin—prostate cancer	4.22e-05	0.000263	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—prostate cancer	4.21e-05	0.000263	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	4.2e-05	0.00102	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	4.18e-05	0.00102	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTA2—prostate cancer	4.15e-05	0.00101	CbGpPWpGaD
Rifaximin—Back pain—Epirubicin—prostate cancer	4.14e-05	0.000258	CcSEcCtD
Rifaximin—Feeling abnormal—Capecitabine—prostate cancer	4.13e-05	0.000258	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—prostate cancer	4.12e-05	0.000257	CcSEcCtD
Rifaximin—Dizziness—Etoposide—prostate cancer	4.12e-05	0.000257	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—prostate cancer	4.11e-05	0.000257	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	4.1e-05	0.000999	CbGpPWpGaD
Rifaximin—Gastrointestinal pain—Capecitabine—prostate cancer	4.1e-05	0.000256	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—prostate cancer	4.1e-05	0.000256	CcSEcCtD
Rifaximin—Body temperature increased—Docetaxel—prostate cancer	4.09e-05	0.000255	CcSEcCtD
Rifaximin—Abdominal pain—Docetaxel—prostate cancer	4.09e-05	0.000255	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Prednisone—prostate cancer	4.07e-05	0.000254	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	4.05e-05	0.000986	CbGpPWpGaD
Rifaximin—Insomnia—Prednisone—prostate cancer	4.04e-05	0.000252	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTA1—prostate cancer	4.01e-05	0.000976	CbGpPWpGaD
Rifaximin—Mental disorder—Doxorubicin—prostate cancer	3.98e-05	0.000249	CcSEcCtD
Rifaximin—Urticaria—Capecitabine—prostate cancer	3.98e-05	0.000248	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—prostate cancer	3.97e-05	0.000248	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—NAT2—prostate cancer	3.96e-05	0.000965	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTO1—prostate cancer	3.96e-05	0.000965	CbGpPWpGaD
Rifaximin—Body temperature increased—Capecitabine—prostate cancer	3.96e-05	0.000247	CcSEcCtD
Rifaximin—Abdominal pain—Capecitabine—prostate cancer	3.96e-05	0.000247	CcSEcCtD
Rifaximin—Vomiting—Etoposide—prostate cancer	3.96e-05	0.000247	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—prostate cancer	3.96e-05	0.000247	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—prostate cancer	3.95e-05	0.000247	CcSEcCtD
Rifaximin—Rash—Etoposide—prostate cancer	3.93e-05	0.000245	CcSEcCtD
Rifaximin—Dermatitis—Etoposide—prostate cancer	3.92e-05	0.000245	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	3.91e-05	0.000952	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	3.91e-05	0.000952	CbGpPWpGaD
Rifaximin—Headache—Etoposide—prostate cancer	3.9e-05	0.000244	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—prostate cancer	3.9e-05	0.000243	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—SIRT1—prostate cancer	3.88e-05	0.000946	CbGpPWpGaD
Rifaximin—Decreased appetite—Prednisone—prostate cancer	3.88e-05	0.000242	CcSEcCtD
Rifaximin—Malaise—Epirubicin—prostate cancer	3.86e-05	0.000241	CcSEcCtD
Rifaximin—Fatigue—Prednisone—prostate cancer	3.85e-05	0.00024	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—prostate cancer	3.84e-05	0.00024	CcSEcCtD
Rifaximin—Syncope—Epirubicin—prostate cancer	3.83e-05	0.000239	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—prostate cancer	3.83e-05	0.000239	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—VDR—prostate cancer	3.83e-05	0.000932	CbGpPWpGaD
Rifaximin—Constipation—Prednisone—prostate cancer	3.82e-05	0.000238	CcSEcCtD
Rifaximin—Hypersensitivity—Docetaxel—prostate cancer	3.81e-05	0.000238	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—prostate cancer	3.8e-05	0.000238	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	3.8e-05	0.000925	CbGpPWpGaD
Rifaximin—Loss of consciousness—Epirubicin—prostate cancer	3.76e-05	0.000235	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	3.75e-05	0.000913	CbGpPWpGaD
Rifaximin—Cough—Epirubicin—prostate cancer	3.73e-05	0.000233	CcSEcCtD
Rifaximin—Asthenia—Docetaxel—prostate cancer	3.71e-05	0.000232	CcSEcCtD
Rifaximin—Nausea—Etoposide—prostate cancer	3.7e-05	0.000231	CcSEcCtD
Rifaximin—Hypersensitivity—Capecitabine—prostate cancer	3.69e-05	0.00023	CcSEcCtD
Rifaximin—Feeling abnormal—Prednisone—prostate cancer	3.68e-05	0.00023	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—prostate cancer	3.67e-05	0.000229	CcSEcCtD
Rifaximin—Pruritus—Docetaxel—prostate cancer	3.66e-05	0.000229	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—prostate cancer	3.66e-05	0.000228	CcSEcCtD
Rifaximin—Gastrointestinal pain—Prednisone—prostate cancer	3.65e-05	0.000228	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—prostate cancer	3.64e-05	0.000227	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—prostate cancer	3.64e-05	0.000227	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—prostate cancer	3.64e-05	0.000227	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.62e-05	0.000226	CcSEcCtD
Rifaximin—Discomfort—Epirubicin—prostate cancer	3.6e-05	0.000225	CcSEcCtD
Rifaximin—Asthenia—Capecitabine—prostate cancer	3.59e-05	0.000224	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—prostate cancer	3.57e-05	0.000223	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—prostate cancer	3.56e-05	0.000222	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—prostate cancer	3.55e-05	0.000222	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—prostate cancer	3.55e-05	0.000222	CcSEcCtD
Rifaximin—Urticaria—Prednisone—prostate cancer	3.54e-05	0.000221	CcSEcCtD
Rifaximin—Pruritus—Capecitabine—prostate cancer	3.54e-05	0.000221	CcSEcCtD
Rifaximin—Diarrhoea—Docetaxel—prostate cancer	3.54e-05	0.000221	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	3.53e-05	0.00086	CbGpPWpGaD
Rifaximin—Abdominal pain—Prednisone—prostate cancer	3.53e-05	0.00022	CcSEcCtD
Rifaximin—Body temperature increased—Prednisone—prostate cancer	3.53e-05	0.00022	CcSEcCtD
Rifaximin—Confusional state—Epirubicin—prostate cancer	3.52e-05	0.00022	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—ERCC2—prostate cancer	3.5e-05	0.000852	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	3.49e-05	0.000851	CbGpPWpGaD
Rifaximin—Anaphylactic shock—Epirubicin—prostate cancer	3.49e-05	0.000218	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	3.48e-05	0.000849	CbGpPWpGaD
Rifaximin—Loss of consciousness—Doxorubicin—prostate cancer	3.48e-05	0.000217	CcSEcCtD
Rifaximin—Infection—Epirubicin—prostate cancer	3.47e-05	0.000216	CcSEcCtD
Rifaximin—Cough—Doxorubicin—prostate cancer	3.45e-05	0.000216	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NR3C1—prostate cancer	3.44e-05	0.000839	CbGpPWpGaD
Rifaximin—Shock—Epirubicin—prostate cancer	3.43e-05	0.000214	CcSEcCtD
Rifaximin—Diarrhoea—Capecitabine—prostate cancer	3.43e-05	0.000214	CcSEcCtD
Rifaximin—Nervous system disorder—Epirubicin—prostate cancer	3.42e-05	0.000214	CcSEcCtD
Rifaximin—Dizziness—Docetaxel—prostate cancer	3.42e-05	0.000214	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—prostate cancer	3.39e-05	0.000212	CcSEcCtD
Rifaximin—Hyperhidrosis—Epirubicin—prostate cancer	3.37e-05	0.000211	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—prostate cancer	3.37e-05	0.00021	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—prostate cancer	3.37e-05	0.00021	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—prostate cancer	3.37e-05	0.00021	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.35e-05	0.000209	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—prostate cancer	3.33e-05	0.000208	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—prostate cancer	3.33e-05	0.000208	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	3.32e-05	0.000809	CbGpPWpGaD
Rifaximin—Dizziness—Capecitabine—prostate cancer	3.31e-05	0.000207	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—prostate cancer	3.29e-05	0.000206	CcSEcCtD
Rifaximin—Vomiting—Docetaxel—prostate cancer	3.29e-05	0.000205	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisone—prostate cancer	3.29e-05	0.000205	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	3.29e-05	0.000801	CbGpPWpGaD
Rifaximin—Rash—Docetaxel—prostate cancer	3.26e-05	0.000204	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—prostate cancer	3.26e-05	0.000204	CcSEcCtD
Rifaximin—Dermatitis—Docetaxel—prostate cancer	3.26e-05	0.000204	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—prostate cancer	3.26e-05	0.000203	CcSEcCtD
Rifaximin—Headache—Docetaxel—prostate cancer	3.24e-05	0.000202	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—prostate cancer	3.23e-05	0.000202	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—PPARA—prostate cancer	3.23e-05	0.000786	CbGpPWpGaD
Rifaximin—Infection—Doxorubicin—prostate cancer	3.21e-05	0.0002	CcSEcCtD
Rifaximin—Asthenia—Prednisone—prostate cancer	3.2e-05	0.0002	CcSEcCtD
Rifaximin—Vomiting—Capecitabine—prostate cancer	3.19e-05	0.000199	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.18e-05	0.000199	CcSEcCtD
Rifaximin—Shock—Doxorubicin—prostate cancer	3.18e-05	0.000198	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—HPGDS—prostate cancer	3.17e-05	0.000772	CbGpPWpGaD
Rifaximin—Nervous system disorder—Doxorubicin—prostate cancer	3.17e-05	0.000198	CcSEcCtD
Rifaximin—Rash—Capecitabine—prostate cancer	3.16e-05	0.000197	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—MYC—prostate cancer	3.16e-05	0.000769	CbGpPWpGaD
Rifaximin—Pruritus—Prednisone—prostate cancer	3.16e-05	0.000197	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—prostate cancer	3.16e-05	0.000197	CcSEcCtD
Rifaximin—Dermatitis—Capecitabine—prostate cancer	3.16e-05	0.000197	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	3.15e-05	0.000767	CbGpPWpGaD
Rifaximin—Headache—Capecitabine—prostate cancer	3.14e-05	0.000196	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—prostate cancer	3.14e-05	0.000196	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—prostate cancer	3.12e-05	0.000195	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—prostate cancer	3.11e-05	0.000194	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	3.1e-05	0.000756	CbGpPWpGaD
Rifaximin—Anorexia—Doxorubicin—prostate cancer	3.08e-05	0.000192	CcSEcCtD
Rifaximin—Nausea—Docetaxel—prostate cancer	3.07e-05	0.000192	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTT1—prostate cancer	3.07e-05	0.000748	CbGpPWpGaD
Rifaximin—Diarrhoea—Prednisone—prostate cancer	3.05e-05	0.000191	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	3.04e-05	0.00074	CbGpPWpGaD
Rifaximin—Decreased appetite—Epirubicin—prostate cancer	3.03e-05	0.000189	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—prostate cancer	3.02e-05	0.000188	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—prostate cancer	3.01e-05	0.000188	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—prostate cancer	3.01e-05	0.000188	CcSEcCtD
Rifaximin—Pain—Epirubicin—prostate cancer	2.98e-05	0.000186	CcSEcCtD
Rifaximin—Constipation—Epirubicin—prostate cancer	2.98e-05	0.000186	CcSEcCtD
Rifaximin—Nausea—Capecitabine—prostate cancer	2.98e-05	0.000186	CcSEcCtD
Rifaximin—Dizziness—Prednisone—prostate cancer	2.95e-05	0.000184	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.94e-05	0.000184	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—ESR1—prostate cancer	2.92e-05	0.000712	CbGpPWpGaD
Rifaximin—Insomnia—Doxorubicin—prostate cancer	2.92e-05	0.000182	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	2.91e-05	0.00071	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	2.91e-05	0.000708	CbGpPWpGaD
Rifaximin—Dyspnoea—Doxorubicin—prostate cancer	2.88e-05	0.00018	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—prostate cancer	2.88e-05	0.00018	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	2.87e-05	0.000699	CbGpPWpGaD
Rifaximin—Gastrointestinal pain—Epirubicin—prostate cancer	2.85e-05	0.000178	CcSEcCtD
Rifaximin—Vomiting—Prednisone—prostate cancer	2.84e-05	0.000177	CcSEcCtD
Rifaximin—Rash—Prednisone—prostate cancer	2.81e-05	0.000176	CcSEcCtD
Rifaximin—Dermatitis—Prednisone—prostate cancer	2.81e-05	0.000176	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—prostate cancer	2.81e-05	0.000175	CcSEcCtD
Rifaximin—Headache—Prednisone—prostate cancer	2.8e-05	0.000175	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.79e-05	0.000174	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—prostate cancer	2.78e-05	0.000174	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—prostate cancer	2.77e-05	0.000173	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—NCOA2—prostate cancer	2.77e-05	0.000675	CbGpPWpGaD
Rifaximin—Pain—Doxorubicin—prostate cancer	2.76e-05	0.000172	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—prostate cancer	2.76e-05	0.000172	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—prostate cancer	2.76e-05	0.000172	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—prostate cancer	2.76e-05	0.000172	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—prostate cancer	2.66e-05	0.000166	CcSEcCtD
Rifaximin—Nausea—Prednisone—prostate cancer	2.65e-05	0.000166	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—prostate cancer	2.64e-05	0.000165	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	2.58e-05	0.000629	CbGpPWpGaD
Rifaximin—Hypersensitivity—Epirubicin—prostate cancer	2.57e-05	0.000161	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—prostate cancer	2.57e-05	0.00016	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—CREBBP—prostate cancer	2.56e-05	0.000624	CbGpPWpGaD
Rifaximin—Abdominal pain—Doxorubicin—prostate cancer	2.55e-05	0.000159	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—prostate cancer	2.55e-05	0.000159	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	2.55e-05	0.00062	CbGpPWpGaD
Rifaximin—Asthenia—Epirubicin—prostate cancer	2.5e-05	0.000156	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—prostate cancer	2.47e-05	0.000154	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	2.45e-05	0.000596	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	2.41e-05	0.000588	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SERPINE1—prostate cancer	2.4e-05	0.000585	CbGpPWpGaD
Rifaximin—Diarrhoea—Epirubicin—prostate cancer	2.39e-05	0.000149	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—prostate cancer	2.38e-05	0.000149	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GGT1—prostate cancer	2.37e-05	0.000578	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2.34e-05	0.000569	CbGpPWpGaD
Rifaximin—Asthenia—Doxorubicin—prostate cancer	2.32e-05	0.000145	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—prostate cancer	2.31e-05	0.000144	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.3e-05	0.000561	CbGpPWpGaD
Rifaximin—Pruritus—Doxorubicin—prostate cancer	2.28e-05	0.000143	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.27e-05	0.000553	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.22e-05	0.000541	CbGpPWpGaD
Rifaximin—Vomiting—Epirubicin—prostate cancer	2.22e-05	0.000139	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—prostate cancer	2.21e-05	0.000138	CcSEcCtD
Rifaximin—Rash—Epirubicin—prostate cancer	2.2e-05	0.000137	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—prostate cancer	2.2e-05	0.000137	CcSEcCtD
Rifaximin—Headache—Epirubicin—prostate cancer	2.19e-05	0.000137	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—COMT—prostate cancer	2.14e-05	0.000521	CbGpPWpGaD
Rifaximin—Dizziness—Doxorubicin—prostate cancer	2.14e-05	0.000133	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.13e-05	0.000519	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.11e-05	0.000514	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.1e-05	0.000512	CbGpPWpGaD
Rifaximin—Nausea—Epirubicin—prostate cancer	2.07e-05	0.000129	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—prostate cancer	2.05e-05	0.000128	CcSEcCtD
Rifaximin—Rash—Doxorubicin—prostate cancer	2.04e-05	0.000127	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—prostate cancer	2.03e-05	0.000127	CcSEcCtD
Rifaximin—Headache—Doxorubicin—prostate cancer	2.02e-05	0.000126	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTM1—prostate cancer	1.96e-05	0.000477	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	1.93e-05	0.00047	CbGpPWpGaD
Rifaximin—Nausea—Doxorubicin—prostate cancer	1.92e-05	0.00012	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	1.86e-05	0.000452	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HAO1—prostate cancer	1.83e-05	0.000446	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	1.83e-05	0.000446	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MYC—prostate cancer	1.52e-05	0.00037	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CBR1—prostate cancer	1.49e-05	0.000364	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ADI1—prostate cancer	1.49e-05	0.000364	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PSAT1—prostate cancer	1.49e-05	0.000364	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CSAD—prostate cancer	1.49e-05	0.000364	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GRHL1—prostate cancer	1.49e-05	0.000364	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TST—prostate cancer	1.49e-05	0.000364	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GRHPR—prostate cancer	1.39e-05	0.000338	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CKMT2—prostate cancer	1.39e-05	0.000338	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.39e-05	0.000338	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.39e-05	0.000338	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NAGLU—prostate cancer	1.3e-05	0.000318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM3—prostate cancer	1.3e-05	0.000318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—RFK—prostate cancer	1.3e-05	0.000318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.3e-05	0.000318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AOX1—prostate cancer	1.3e-05	0.000318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PGAM2—prostate cancer	1.3e-05	0.000318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.3e-05	0.000318	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AMACR—prostate cancer	1.24e-05	0.000301	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.24e-05	0.000301	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NAT1—prostate cancer	1.24e-05	0.000301	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.24e-05	0.000301	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—DEGS1—prostate cancer	1.24e-05	0.000301	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.18e-05	0.000287	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—prostate cancer	1.05e-05	0.000257	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.05e-05	0.000256	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HPGD—prostate cancer	1.05e-05	0.000256	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TNFRSF21—prostate cancer	9.89e-06	0.000241	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTAP—prostate cancer	9.62e-06	0.000234	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP7B1—prostate cancer	9.62e-06	0.000234	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SRD5A1—prostate cancer	9.37e-06	0.000228	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SULT1E1—prostate cancer	9.37e-06	0.000228	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD17B3—prostate cancer	8.94e-06	0.000218	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ACSL4—prostate cancer	8.94e-06	0.000218	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UMPS—prostate cancer	8.57e-06	0.000209	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PHGDH—prostate cancer	8.57e-06	0.000209	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ARG2—prostate cancer	8.57e-06	0.000209	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LDHB—prostate cancer	8.41e-06	0.000205	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP3A5—prostate cancer	8.25e-06	0.000201	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UCP3—prostate cancer	7.97e-06	0.000194	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TCN2—prostate cancer	7.97e-06	0.000194	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PDHA1—prostate cancer	7.97e-06	0.000194	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA3—prostate cancer	7.97e-06	0.000194	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD3B1—prostate cancer	7.6e-06	0.000185	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC22A3—prostate cancer	7.6e-06	0.000185	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA4—prostate cancer	7.29e-06	0.000178	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TBXAS1—prostate cancer	7.29e-06	0.000178	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA2—prostate cancer	7.1e-06	0.000173	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCG5—prostate cancer	7.02e-06	0.000171	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SULT1A1—prostate cancer	7.02e-06	0.000171	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTA1—prostate cancer	6.85e-06	0.000167	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD3B2—prostate cancer	6.78e-06	0.000165	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTO1—prostate cancer	6.78e-06	0.000165	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NAT2—prostate cancer	6.78e-06	0.000165	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2C18—prostate cancer	6.5e-06	0.000158	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LRP2—prostate cancer	6.5e-06	0.000158	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PLCB2—prostate cancer	6.5e-06	0.000158	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—P4HB—prostate cancer	6.37e-06	0.000155	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC22A1—prostate cancer	6.2e-06	0.000151	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SULT2A1—prostate cancer	6.04e-06	0.000147	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MED12—prostate cancer	5.94e-06	0.000145	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GNG5—prostate cancer	5.9e-06	0.000144	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOA3—prostate cancer	5.68e-06	0.000138	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HPGDS—prostate cancer	5.42e-06	0.000132	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2C19—prostate cancer	5.38e-06	0.000131	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTT1—prostate cancer	5.25e-06	0.000128	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ACHE—prostate cancer	5.25e-06	0.000128	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2A6—prostate cancer	5.19e-06	0.000127	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.05e-06	0.000123	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PRKACB—prostate cancer	5.03e-06	0.000122	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.97e-06	0.000121	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOA2—prostate cancer	4.74e-06	0.000115	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.52e-06	0.00011	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.42e-06	0.000108	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NQO1—prostate cancer	4.37e-06	0.000106	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TH—prostate cancer	4.3e-06	0.000105	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.19e-06	0.000102	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GGT1—prostate cancer	4.05e-06	9.88e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOA1—prostate cancer	3.99e-06	9.73e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.94e-06	9.59e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—RXRA—prostate cancer	3.8e-06	9.25e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—COMT—prostate cancer	3.66e-06	8.91e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTP1—prostate cancer	3.64e-06	8.87e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ITPR1—prostate cancer	3.58e-06	8.73e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TYMS—prostate cancer	3.39e-06	8.25e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM1—prostate cancer	3.35e-06	8.15e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LPL—prostate cancer	3.29e-06	8e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.17e-06	7.73e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ERCC2—prostate cancer	3.15e-06	7.67e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTHFR—prostate cancer	2.96e-06	7.21e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARA—prostate cancer	2.9e-06	7.07e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CAV1—prostate cancer	2.73e-06	6.65e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.49e-06	6.05e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—INS—prostate cancer	2.35e-06	5.73e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CREBBP—prostate cancer	2.3e-06	5.61e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.18e-06	5.32e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NOS3—prostate cancer	2.06e-06	5.03e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.9e-06	4.64e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTGS2—prostate cancer	1.89e-06	4.6e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTEN—prostate cancer	1.65e-06	4.01e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—EP300—prostate cancer	1.57e-06	3.82e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.16e-06	2.83e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—prostate cancer	9.48e-07	2.31e-05	CbGpPWpGaD
